ATAI (AtaiBeckley) Tariff Resilience Score: 9/10 (As of Jul. 06, 2026)


ATAI AtaiBeckley Inc ATAI
56 GF Score
Price $5.19
GF Value $7.24
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is AtaiBeckley Tariff Resilience Score?

AtaiBeckley ATAI +6.57% 56 Tariff Resilience Score is 9 as of Jul. 06, 2026. GuruFocus rates ATAI with a GF Score™ of 56/100 and a GF Value™ of $7.24 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,369 Biotechnology companies, AtaiBeckley ranks better than 99.93% on this metric.

AtaiBeckley has the Tariff Resilience Score of 9, which implies that the company might have Highly Resilient.

AtaiBeckley has ATAI Life Sciences NV has minimal tariff exposure as a biotech firm. Its operations are primarily research-focused, with limited reliance on international supply chains. Historical tariff changes have had little impact.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes AtaiBeckley might have Highly Resilient.

AtaiBeckley  (NAS:ATAI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

AtaiBeckley Tariff Resilience Score Related Terms

ATAI vs GHRS, NUVB, VRDN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, AtaiBeckley's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AtaiBeckley Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AtaiBeckley's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where AtaiBeckley's Tariff Resilience Score falls into.


ATAI
56GF Score
AtaiBeckley Inc ATAI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 9 mean?
AtaiBeckley (ATAI) has a Tariff Resilience Score of 9 as of Jul. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, AtaiBeckley ranks #1 out of 1369 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is AtaiBeckley's Tariff Resilience Score too high?
AtaiBeckley's current Tariff Resilience Score is 9. The Biotechnology industry median Tariff Resilience Score is 4.00. AtaiBeckley's value of 9 is 125% above this industry median. Based on the distribution chart, AtaiBeckley ranks #1 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AtaiBeckley has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AtaiBeckley's Tariff Resilience Score compare to GHRS and NUVB?
According to the Biotechnology industry distribution chart, AtaiBeckley ranks #1 out of 1369 companies for Tariff Resilience Score. This places AtaiBeckley in the top 0% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. AtaiBeckley's value of 9 is 125% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AtaiBeckley's current Tariff Resilience Score of 9 is 125% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtaiBeckley's current Tariff Resilience Score is 9. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtaiBeckley stock overvalued right now?
Based on GuruFocus' analysis, AtaiBeckley (ATAI) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.24, compared to a current price of $5.19 — trading 28.3% below its estimated fair value. The current Tariff Resilience Score is 9 and 125% above the Biotechnology industry median of 4.00. AtaiBeckley's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For AtaiBeckley (ATAI), the current Tariff Resilience Score is 9 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AtaiBeckley (ATAI) Overvalued in 2026?

Based on GuruFocus' analysis, AtaiBeckley stock appears to be undervalued. The current stock price of $5.19 is trading 28.3% below its estimated GF Value™ of $7.24. GuruFocus considers AtaiBeckley to be Modestly Undervalued.

Key valuation signals for ATAI:

  • Tariff Resilience Score: 9
  • GF Value™: $7.24 vs. price of $5.19 (28.3% below fair value)
  • GF Score™: 56/100 with 6 warning signs
  • Industry Position: 125% above the Biotechnology median (#1 of 1369)

No single metric tells the full story. See the ATAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AtaiBeckley Business Description

Other Exchanges B72:Germany
Address 250 West 34th Street, New York, NY, USA, 10119
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
56GF Score

Get the complete analysis for ATAI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.19
Price
$7.24
GF Value